Figma Shares Indicated To Open $105/$110
LONDON - Solvonis Therapeutics plc (LSE:SVNS) has initiated an artificial intelligence-supported drug discovery program focused on its central nervous system compound library, the company announced Wednesday.
The program will utilize AI and computational modeling techniques to analyze the company’s proprietary CNS compound library, which was acquired through its recent purchase of Awakn Life Sciences Corp. This library contains multiple patent-pending chemical series developed through a completed hit-to-lead program that included in silico design, in vitro screening, and in vivo characterization.
Under the direction of Chief Scientific Officer Professor David Nutt, the AI program will initially focus on identifying potential treatments for depression and stimulant use disorders.
"The integration of AI supported analytics into our discovery workflow enhances our ability to identify high-potential compounds for further development," said Nutt in the press release statement.
The initiative aims to accelerate the identification and optimization of development candidates within the library through data-driven asset prioritization, structure-activity relationship analysis, and translational hypothesis generation.
This new program operates separately from Solvonis’ existing preclinical program, SVN-SDN-014, which targets post-traumatic stress disorder. Together with the company’s late-stage clinical assets in Alcohol Use Disorder, these efforts form what the company describes as a diversified R&D pipeline targeting neuropsychiatric conditions.
Solvonis, a clinical-stage biopharmaceutical company, develops treatments for addiction and mental health disorders. The company’s announcement comes as part of its strategy following the Awakn acquisition to leverage the newly acquired compound library.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.